SynthesisThe Cochrane database of systematic reviews2000
Calcium antagonists for acute ischemic stroke.
Synthesis in The Cochrane database of systematic reviews, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 8 syntheses or guidelines pooled it, 102 citations in OpenAlex.
- Calcium antagonists for acute ischemic stroke.The Cochrane database of systematic reviews · 2019Pooled it
- Gamma aminobutyric acid (GABA) receptor agonists for acute stroke.The Cochrane database of systematic reviews · 2018Pooled it
- Cerebrolysin for acute ischaemic stroke.The Cochrane database of systematic reviews · 2017Pooled it
- Cerebrolysin for acute ischaemic stroke.The Cochrane database of systematic reviews · 2016Pooled it
- Gamma aminobutyric acid (GABA) receptor agonists for acute stroke.The Cochrane database of systematic reviews · 2016Pooled it
- Vasoactive drugs for acute stroke.The Cochrane database of systematic reviews · 2010Pooled it
- Effect of early treatment with anti-hypertensive drugs on short and long-term mortality in patients with an acute cardiovascular event.The Cochrane database of systematic reviews · 2009Pooled it
- Grey literature in meta-analyses of randomized trials of health care interventions.The Cochrane database of systematic reviews · 2007Pooled it
- L-type CaScience signaling · 2020Article
- Can prospective systematic reviews of animal studies improve clinical translation?Journal of translational medicine · 2020Article
- Ischaemic and hypoxic conditioning: potential for protection of vital organs.Experimental physiology · 2019Review
- Blood pressure management in acute stroke.Stroke and vascular neurology · 2016Review
- Systematic reviews of preclinical animal studies can make significant contributions to health care and more transparent translational medicine.The Cochrane database of systematic reviews · 2014Article
- The Pathophysiologic Roles of TRPM7 Channel.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2014Review
- Advances in stroke therapy.Drug delivery and translational research · 2011Article
- Stroke management.Annals of Indian Academy of Neurology · 2011Article
- TRPM7 in cerebral ischemia and potential target for drug development in stroke.Acta pharmacologica Sinica · 2011Review
- Why do we need multifunctional neuroprotective and neurorestorative drugs for Parkinson's and Alzheimer's disorders?Rambam Maimonides medical journal · 2010Article
- Why do we need multifunctional neuroprotective and neurorestorative drugs for Parkinson's and Alzheimer's diseases as disease modifying agents.Experimental neurobiology · 2010Article
- Neuroprotection for ischemic stroke: past, present and future.Neuropharmacology · 2008Review
Corrections and comments
- Updated by
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe sudden loss of blood supply in ischemic stroke is associated with increased levels of calcium ions within neurones. Inhibiting this increase could protect neurones and is thought to reduce neurological impairment, disability and handicap after stroke.
objectivesThe aim of this review is to determine whether calcium antagonists reduce the risk of death or dependency after acute ischemic stroke. The influence of different drugs, dosages, routes of administration, time intervals after stroke and trial design on the risk of poor outcome was investigated. SEARCH STRATEGY: Relevant trials were identified in the Specialised Register of Controlled Trials (last searched: March 1999). SELECTION CRITERIA: All truly randomised trials comparing a calcium antagonist with control in patients with acute ischaemic stroke were included. DATA COLLECTION AND ANALYSIS: Two authors assessed all trials and extracted the data. Poor outcome, defined as death or dependency in activities of daily living, was used as the main outcome. Analyses were, if possible, "intention-to-treat". MAIN
results46 trials were identified of which 28 were included (7521 patients). No effect of calcium antagonists on poor outcome at the end of follow-up (OR 1.07, 95% CI 0.97/1.18), or on death at end of follow-up (OR 1.10, 95% CI 0.98/1.24) was found. Intravenous administration (i.v.) of calcium antagonists was associated with an increase in the number of patients with poor outcome compared to oral administration (indirect comparisons). Comparisons of different doses of nimodipine suggested that the highest doses were associated with poorer outcome. Administration within 12 hours of onset was associated with an increase in the proportion of patients with poor outcome, but this effect was largely due to the poor results associated with i.v. administration. A subgroup analysis on nimodipine (oral, 120 mg/day) started within 12 hours of stroke onset, did not show a beneficial effect. REVIEWER'S
conclusionsNo evidence is available to justify the use of calcium antagonists in patients with acute ischaemic stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.